Amylyx Pharmaceuticals Reports Q1 2026 Results, Advances Multiple Clinical Programs

summarizeSummary

Amylyx Pharmaceuticals reported Q1 2026 financial results with an increased net loss but highlighted substantial progress in its clinical pipeline, including Phase 3 enrollment completion for avexitide and positive Phase 2 data for AMX0035, while maintaining its cash runway into 2028.

check_boxKey Events · Product Development and Regulatory · AMLX

• Q1 2026 Financial Results

  Reported a net loss of $41.284 million for the three months ended March 31, 2026, an increase from $35.907 million in the prior year period. Research and development expenses increased by 25% to $27.610 million, primarily driven by avexitide and new programs, partially offset by the discontinuation of AMX0035 for PSP.

• Avexitide Phase 3 Enrollment Completed

  Enrollment for the pivotal Phase 3 LUCIDITY clinical trial evaluating avexitide in post-bariatric hypoglycemia (PBH) was completed in March 2026. Topline data is anticipated in the third quarter of 2026, with a potential commercial launch in 2027 if approved. An Expanded Access Program (EAP) for avexitide in PBH was initiated in May 2026.

• AMX0035 Shows Sustained Positive Phase 2 Data

  Positive Week 48 data from the Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome demonstrated continued and sustained improvement in pancreatic beta cell function, glycemic control, and visual acuity. Discussions with the FDA for a Phase 3 trial are ongoing.

• Pipeline Expansion with AMX0318 and AMX0114 Progress

  AMX0318 was selected as a development candidate for PBH and other rare diseases in January 2026, triggering a $4 million milestone payment to Gubra. IND-enabling studies are underway, targeting an IND in 2027. Enrollment for Cohort 2 of the Phase 1 LUMINA trial for AMX0114 in ALS was completed in March 2026, with Cohort 1 biomarker data expected in June 2026.

auto_awesomeAnalysis · AMLX · Life Sciences

Amylyx Pharmaceuticals reported an increased net loss for Q1 2026 but demonstrated significant progress across its clinical pipeline, maintaining a cash runway into 2028. Key advancements include the completion of enrollment for the pivotal Phase 3 LUCIDITY trial for avexitide in PBH, with topline data expected in Q3 2026, and positive long-term data from the Phase 2 HELIOS trial for AMX0035 in Wolfram syndrome. The company also advanced AMX0114 in ALS and selected AMX0318 as a new development candidate, indicating a robust and progressing pipeline. The resolution of a class action lawsuit for $6.5 million, largely covered by insurance, removes a minor legal overhang.